ICRM
EBS icon

Insight Capital Research & Management’s Emergent Biosolutions EBS Stock Holding History

Insight Capital Research & Management’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		$1.27M Buy
+31,437
New +$1.14M 0.72% 61
2016
Q2 		– Sell
-203,367
Closed -$7.39M – 107
2016
Q1 		$7.39M Sell
203,367
-5,052
-2% -$178K 2.29% 4
2015
Q4 		$8.34M Buy
208,419
+1,960
+0.9% +$68.3K 2.43% 4
2015
Q3 		$5.88M Buy
+206,459
New +$6.8M 1.78% 12

Other funds holding EBS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
SCM
Snyder Capital Management San Francisco, California $5.16B AUM 26.72% 1-Year Est. Return

Insight Capital Research & Management's EBS Position: Q3 2017 in Review

Insight Capital Research & Management opened a new position in Emergent Biosolutions (EBS) in Q3 2017: 31,437 shares worth $1.27M. The stake represents 0.72% of the portfolio and ranks #61 among its holdings. This is a return to the name: Insight Capital Research & Management previously reported a position in EBS as recently as Q1 2016.

Insight Capital Research & Management first reported a position in EBS in Q3 2015 and has held it in 4 quarters since. The position peaked at $8.34M in Q4 2015. 198 funds tracked by Wall St. Rank hold EBS as of Q3 2017.

  • Insight Capital Research & Management held 31,437 shares of Emergent Biosolutions worth $1.27M as of Q3 2017.
  • Emergent Biosolutions was a new Insight Capital Research & Management position in Q3 2017.
  • Emergent Biosolutions made up 0.72% of Insight Capital Research & Management's portfolio in Q3 2017, its #61 holding.
  • Insight Capital Research & Management first reported a position in Emergent Biosolutions in Q3 2015 and has held it in 4 quarters since.
  • Insight Capital Research & Management's Emergent Biosolutions position peaked at $8.34M in Q4 2015.
  • 198 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q3 2017.

Based on Insight Capital Research & Management's 13F filing for Q3 2017, filed 15 Nov 2017.